ArticleBMC pulmonary medicine2026
Association between frailty and the risks of chronic pulmonary diseases and lung cancer.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundFrailty, a multidimensional syndrome of decreased physiological reserve, is associated with adverse health outcomes, but its relationship with a broad spectrum of pulmonary diseases remains incompletely understood. This study aimed to systematically evaluate the associations between frailty and multiple pulmonary diseases and their multimorbidity patterns.
methodsWe analyzed 146,747 participants from the UK Biobank. Frailty was quantified using frailty index (FI) and categorized into non-frail, pre-frail, and frail groups. Outcomes included chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease (ILD), lung cancer, their overlap syndromes, and pulmonary-related mortality. Cox proportional hazards models with inverse probability of treatment weighting estimated hazard ratios (HRs) and 95% confidence intervals, adjusting for demographic, lifestyle, environmental, and clinical covariates with competing risk analyses performed using Fine–Gray models. Non-linear associations were assessed using restricted cubic splines, and E-values evaluated robustness to unmeasured confounding. Mediation analyses based on UK Biobank Pharma Proteomics Project (UKB-PPP) identify protein signatures associated with frailty–disease relationships.
resultsFrail individuals showed higher incidence of multiple pulmonary outcomes compared with non-frail and pre-frail participants. Dose-response analyses revealed non-linear associations, with risk elevation evident even at pre-frailty (FI = 0.237) for asthma-COPD overlap. Mediation analyses identified WFDC2 and CXCL17 as proteins associated with both frailty and multiple pulmonary outcomes, including ILD and lung cancer.
conclusionFrailty is associated with a higher incidence of multiple pulmonary diseases and multimorbidity patterns. These associations may be partly accounted for by shared protein signatures. Frailty may serve as a marker for risk stratification in respiratory health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.